OmniAb’s (OABI) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of OmniAb (NASDAQ:OABI) in a research report sent to investors on Thursday morning,Benzinga reports. The brokerage currently has a $11.00 price objective on the stock.

OABI has been the subject of several other research reports. Royal Bank of Canada restated an “outperform” rating and set a $7.00 price target on shares of OmniAb in a research report on Friday, August 16th. Benchmark restated a “buy” rating and set a $8.00 price target on shares of OmniAb in a research report on Monday, August 19th.

OmniAb Stock Down 4.7 %

OABI stock opened at $3.88 on Thursday. OmniAb has a 52-week low of $3.56 and a 52-week high of $6.72. The company’s 50-day simple moving average is $4.18 and its 200-day simple moving average is $4.27. The firm has a market cap of $458.47 million, a P/E ratio of -6.26 and a beta of -0.12.

Institutional Trading of OmniAb

A number of hedge funds have recently bought and sold shares of the business. Barclays PLC raised its holdings in OmniAb by 321.5% in the 3rd quarter. Barclays PLC now owns 143,215 shares of the company’s stock valued at $606,000 after acquiring an additional 109,236 shares during the last quarter. State Street Corp increased its holdings in shares of OmniAb by 1.7% during the 3rd quarter. State Street Corp now owns 2,031,676 shares of the company’s stock worth $8,594,000 after buying an additional 34,654 shares during the last quarter. Murchinson Ltd. acquired a new stake in shares of OmniAb during the 3rd quarter worth approximately $4,230,000. PDT Partners LLC acquired a new stake in shares of OmniAb during the 3rd quarter worth approximately $123,000. Finally, Walleye Capital LLC acquired a new stake in shares of OmniAb during the 3rd quarter worth approximately $61,000. Institutional investors and hedge funds own 72.08% of the company’s stock.

About OmniAb

OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.